MD MEDNAX Inc.

MedData’s New Patient Financial Platform Solves Inefficient, Costly Revenue Cycle Challenges

MedData, Inc., a MEDNAX (NYSE: MD) company and a leading provider of patient-facing financial services for hospitals and health systems, today announced the debut of its comprehensive patient financial platform, MedData OneTouch.

As healthcare shifts from fee-for-service methods and toward a value-based care model, traditional approaches to revenue cycle management are filled with complex and costly challenges, including time and resource inefficiencies, compliance risk, and patient frustration.

“Hospital and health system CFOs nationwide are under tremendous pressure to cut costs, and they are looking for ways to streamline their revenue cycle,” said MedData president and CEO, Ann Barnes. “This new approach is the only one of its kind in the marketplace today – and it’s already proven to be an effective way to reduce costs.”

MedData conducted a 2017 annual performance study with existing clients across a broad range of provider types and found that connecting traditionally siloed services can drastically reduce the inefficient and costly aspects of traditional revenue cycle management. All patient-facing financial programs – including Eligibility, Patient Responsibility, Workers’ Compensation, Denials, Disability, and Third Party Liability – were linked together to identify all payer sources in the properly compliant order.

The unified solution, MedData OneTouch, created a single touchpoint where every patient, whether insured, under-insured, or uninsured, was able to receive the most appropriate coverage for their situation. Hospitals and health systems were able to simultaneously increase overall cost savings and patient satisfaction in addition to capturing incremental revenue purely through combining best-in-class patient financial services into a single process.

What makes MedData OneTouch so unique, says Barnes, is how it delivers one solution for the patient’s entire healthcare financial life cycle.

"Our innovative platform ensures that the patient financial experience is just as great as their clinical one. Because MedData serves as a single touchpoint, patients don’t have to provide the same information over and over again,” Barnes said. “And hospitals don’t have to worry about missing revenue opportunities or the significant compliance risk associated with juggling multiple vendors. Every interaction is seamless, positive, and productive.”

Additional results from the 2017 performance study are included in the white paper "Innovative Revenue Cycle Management Is the Sharpest Blade for Cutting Costs,” available on the MedData website.

About MedData

MedData, a MEDNAX (NYSE: MD) company, is a leading provider of technology-enabled management services for hospitals and health systems that serve the entire patient financial lifecycle from pre-visit through post-discharge while improving the patient experience and helping them engage better with their providers. For four decades, the company has been providing innovative solutions to the medical community and serving hundreds of millions of patients across numerous medical specialties. MedData currently serves more than 10,000 physicians at a growing network of 3,000+ facilities nationwide from its headquarters in Brecksville, Ohio, and more than 20 regional offices across the U.S. To learn more about MedData’s patient-focused solutions platform, please visit the MedData website.

EN
10/04/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MEDNAX Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Pediatrix Medical Group, Inc.: 1 director

A director at Pediatrix Medical Group, Inc. sold/sold after exercising options 33,000 shares at 13.260USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company...

Mednax, Inc.: Covenant Quality Post-Sale Snapshot: $400m 5.375% Senior...

Mednax. Inc.’s covenant package provides lower-tier HY-Lite protection, reflecting a covenant quality score of 5.00.

Mednax, Inc.: Update following upgrade of CFR to Ba3

Our credit view of this issuer reflects its high leverage, offset by its strong competitive position.

Moody's upgrades Mednax's CFR to Ba3; rates new unsecured notes Ba3, o...

Rating Action: Moody's upgrades Mednax's CFR to Ba3; rates new unsecured notes Ba3, outlook stable. Global Credit Research- 01 Feb 2022. New York, February 01, 2022-- Moody's Investors Service upgraded Mednax, Inc.' s Corporate Family Rating to Ba3 from B1 and Probability of Default Rating to Ba3-PD from B1-PD.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch